1 – 39 of 39
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
(
- Contribution to journal › Article
- 2023
-
Mark
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy : A systematic review and meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Protocol for the T-REX-trial : Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases - An open, multicentre, randomised non-inferiority phase 3 trial
(
- Contribution to journal › Article
- 2022
-
Mark
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Evalutation of two commercial deep learning OAR segmentation models for prostate cancer treatment
2022) ESTRO 2022(
- Contribution to conference › Abstract
-
Mark
MRI-only radiotherapy of gliomas – a prospective implementation study.
(
- Contribution to journal › Published meeting abstract
-
Mark
Pelvic U-Net : multi-label semantic segmentation of pelvic organs at risk for radiation therapy anal cancer patients using a deeply supervised shuffle attention convolutional neural network
(
- Contribution to journal › Article
-
Mark
Prospective Clinical Feasibility Study for MRI-Only Brain Radiotherapy
(
- Contribution to journal › Article
- 2021
-
Mark
Quality assessment of locoregional breast cancer radiotherapy in the international SENOMAC-trial.
(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical validation of a commercially available deep learning software for synthetic CT generation for brain
(
- Contribution to journal › Article
- 2020
-
Mark
Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer
(
- Contribution to journal › Article
-
Mark
MRI-only based treatment with a commercial deep-learning generation method for synthetic CT of brain
(
- Contribution to conference › Abstract
- 2019
-
Mark
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
(
- Contribution to journal › Article
-
Mark
Comparative treatment planning study for mediastinal Hodgkin’s lymphoma : impact on normal tissue dose using deep inspiration breath hold proton and photon therapy
(
- Contribution to journal › Article
-
Mark
Surface guided radiotherapy (SGRT) improves breast cancer patient setup accuracy
(
- Contribution to journal › Article
-
Mark
Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes
(
- Contribution to journal › Article
-
Mark
Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Stability of oestrogen and progesterone receptor antigenicity in formalin‐fixed paraffin‐embedded breast cancer tissue over time
(
- Contribution to journal › Article
-
Mark
Surface guided radiotherapy decreases the uncertainty in breast cancer patient setup
2018) 60th AAPM Annual Meeting & Exhibition(
- Contribution to conference › Abstract
-
Mark
Surface guided radiotherapy increases setup accuracy for locoregional breast cancer patients
(
- Contribution to journal › Published meeting abstract
- 2017
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffinblocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
(
- Contribution to journal › Article
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
(
- Contribution to conference › Abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Dosimetric Benefits From Deep Inspiration Proton and Photon Therapy for Hodgkin Lymphoma
2016) American Society of Radiation Oncology In International Journal of Radiation Oncology Biology Physics 96(2, Suppl 1). p.662-663(
- Contribution to journal › Published meeting abstract
- 2015
-
Mark
Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
(
- Contribution to journal › Article
-
Mark
Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
(
- Contribution to journal › Article
-
Mark
T1-mapping and OE-MRI of patients treated with radiotherapy for breast cancer
2015) 7th International Workshop on Pulmonary Functional Imaging(
- Contribution to conference › Poster
- 2013
-
Mark
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(
- Contribution to journal › Article
-
Mark
Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast cancer
(
- Contribution to journal › Article
-
Mark
Regarding the letter to the editor 'AIB1 and its significant role in tumor pathogenesis in systemic malignancies: beyond breast carcinomas' by Kapoor and Shailendra in Annals of Oncology.
(
- Contribution to journal › Letter
- 2012
-
Mark
Predicting Prognosis and Tamoxifen Response in Breast Cancer. With a special focus on contralateral breast cancer.
(
- Thesis › Doctoral thesis (compilation)
- 2011
-
Mark
Regarding the article "The p160 ER co-regulators predict outcome in ER negative breast cancer" by Spears, Oesterreich, Migliaccio et al. published in Breast Cancer Res Treat, March 2011.
(
- Contribution to journal › Article
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer.
(
- Contribution to journal › Article
- 2010
-
Mark
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
(
- Contribution to journal › Article
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
(
- Contribution to journal › Article
- 2008
-
Mark
High amplified in breast cancer 1 is a significant predictor of improved response to adjuvant tamoxifen in premenopausal women
2008) 31st Annual San Antonio Breast Cancer Symposium(
- Contribution to conference › Abstract